Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2026
Reporting Period: Single event date (June 16, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. The filing serves as a Regulation FD disclosure regarding a specific product development milestone.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The filing reports a material non-financial event rather than a change in financial performance compared to a prior period. The material change is the initiation of a new clinical/regulatory study:
- Event: Initiation of an Interference Study.
- Purpose: To support the FDA 510(k) submission for U.S. market clearance.
- Product: Intelligent Fingerprinting Drug Screening System.
- Specific Target: Detection of the opiate codeine.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) to announce the study initiation. The disclosure is qualified in its entirety by the full text of that press release.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainty of regulatory submissions. The success of the 510(k) clearance is contingent upon the results of the Interference Study and subsequent FDA review.
Guidance: No financial guidance or forward-looking revenue projections are provided in this filing.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) for specific details on the study design and timeline.
- Confirm the status of the FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System.
- Monitor future filings for the results of the Interference Study regarding codeine detection.
- Review the Company's latest 10-K or 10-Q for current financial health, as this 8-K contains no financial data.